In advanced CKD, ACEis or ARBs reduce kidney failure vs. placebo or non-RAAS inhibitors at 34 mo.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 39348707.
- Also identified by DOI 10.7326/ANNALS-24-02169-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ku E, Inker LA, Tighiouart H, et al. <b>Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials.</b> Ann Intern Med. 2024;177:953-963. 38950402.